Status: Recruiting
Changes in the Impact of Genitourinary Syndrome of Menopause With a Novel Nonhormonal Vulvovaginal Gel Assessed by PROMs.
The goal of this clinical trial is to improve the management of Genitourinary syndrome of menopause (GSM) to preliminary assess safety and effectivity of a novel hormone-free mucosa composition (XCMIM20m) applied topically to the vulvovaginal area. Symptoms of vaginal atrophy will be compared before and after 8 weeks of use of the tested gel with the Day-to-Day Impact of Vaginal Aging (DIVA) PROMs questionnaire to assess changes impact of GSM symptoms.
Participants needed: 80
Trial details
Age: 40-70Biological sex: FemaleType: InterventionalSponsor: Mucosa Innovations, S.L.Updated: Mar 30, 2026Locations: 1
Eligibility criteria
Patient has to have at least one symptom of GSM or suffer from symptoms related... [+4]
Patients that do not want to fill the questionnaire, especially the questions th... [+12]